Aurobindo Pharma Ltd
AUROPHARMABSE 524804PharmaceuticalsMkt cap ₹96,376 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹9,150 Cr
YoY +16.3%QoQ +3.4%
Net profit · Q1 FY27
₹1,032 Cr
YoY +25.2%QoQ +12.1%
Net margin · Q1 FY27
11.3%
+0.8 pts vs Q1 FY26
Net profit · FY26
₹3,503 Cr
YoY +0.6%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 9,150 | 8,853 | 8,646 | 8,286 | 7,868 | +16.3% |
| Other income | 264 | 117 | 188 | 121 | 105 | +150.9% |
| Total income | 9,415 | 8,970 | 8,834 | 8,406 | 7,973 | +18.1% |
| Profit before tax | 1,517 | 1,293 | 1,338 | 1,274 | 1,205 | +25.9% |
| Tax | 483 | 370 | 429 | 428 | 383 | +26.3% |
| Net profit | 1,032 | 921 | 910 | 848 | 824 | +25.2% |
| Net margin | 11.3% | 10.4% | 10.5% | 10.2% | 10.5% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 33,653 | 31,724 | 29,002 | 24,855 | 23,455 | +6.1% |
| Other income | 492 | 622 | 557 | 291 | 320 | -20.9% |
| Total income | 34,145 | 32,346 | 29,559 | 25,146 | 23,776 | +5.6% |
| Profit before tax | 5,110 | 5,098 | 4,397 | 2,624 | 3,404 | +0.2% |
| Tax | 1,609 | 1,583 | 1,211 | 685 | 726 | +1.7% |
| Net profit | 3,503 | 3,484 | 3,169 | 1,928 | 2,647 | +0.6% |
| Net margin | 10.4% | 11.0% | 10.9% | 7.8% | 11.3% |
BIC's take
We haven't covered Aurobindo Pharma Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:19 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.